Acadia Pharmaceuticals ACAD Stock Issuance Proceeds
Stock Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by Acadia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfCommonStock.
The official record: Acadia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Acadia Pharmaceuticals's stock issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Acadia Pharmaceuticals's stock issuance proceeds?
- Acadia Pharmaceuticals (ACAD) reported stock issuance proceeds of $4.23M in Q1 2026.
- How has Acadia Pharmaceuticals's stock issuance proceeds changed year-over-year?
- Acadia Pharmaceuticals's stock issuance proceeds increased by 130.2% year-over-year, from $1.84M to $4.23M.
- What is the long-term trend for Acadia Pharmaceuticals's stock issuance proceeds?
- Over 4 years (2021 to 2025), Acadia Pharmaceuticals's stock issuance proceeds has grown at a 28.7% compound annual growth rate (CAGR), from $18.16M to $49.88M.
- What does stock issuance proceeds mean?
- Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.